Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis

BMJ Open
Yongliang JiaSiu-Wai Leung

Abstract

Past studies of network meta-analysis focused on evaluating drug combinations in treating type 2 diabetes but not on evaluating antidiabetic drugs in monotherapy. Clinical guidelines (eg, NICE (National Institute of Health and Care Excellence) clinical guidelines 66 and 87) were based only on the findings of individual clinical trials and pairwise meta-analysis in evaluating monotherapy. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare major antidiabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and SGLT-2 (sodium-glucose transporter-2) inhibitors. Randomised controlled trials (RCTs) on the drug therapy of type 2 diabetes with outcome measures including glycosylated haemoglobin or fasting blood glucose will be included. The quality of included RTCs will be evaluated according to the Cochrane Collaboration's risk of bias tool. Traditional pairwise meta-analysis and Bayesian network meta-analysis will be conducted to compare the efficacies of antidiabetic drugs. Sensitivity analysis on the sample size of RCTs, meta-regression analysis on the follow-up periods, dosages and baselines of outcome...Continue Reading

References

Apr 15, 1983·Journal of Immunological Methods·R E Chambers, J T Whicher
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Sep 28, 2004·Statistics in Medicine·G Lu, A E Ades
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenWiro Stam
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Jul 28, 2009·Journal of Clinical Epidemiology·David MoherUNKNOWN PRISMA Group
May 18, 2011·Annals of Internal Medicine·Jorge L GrossUNKNOWN Diabetes and Endocrinology Meta-analysis Group (DEMA)
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenJoseph C Cappelleri
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Dec 1, 2012·Research Synthesis Methods·Gert van ValkenhoefNicky J Welton

❮ Previous
Next ❯

Citations

Sep 20, 2018·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Y JiaS-W Leung

❮ Previous
Next ❯

Software Mentioned

fmsb
metafor
PRISMA
ggplot2
GeMTC
R2WinBUGS
R
WinBUGS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.